Empirical Wealth Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.83M | Buy |
39,051
+1,083
| +3% | +$233K | 0.14% | 110 |
|
|
2026
Q1 | $8.26M | Buy |
37,968
+1,761
| +5% | +$391K | 0.14% | 112 |
|
|
2025
Q4 | $8.27M | Buy |
36,207
+2,833
| +8% | +$645K | 0.15% | 109 |
|
|
2025
Q3 | $7.73M | Buy |
33,374
+222
| +0.7% | +$45.2K | 0.15% | 109 |
|
|
2025
Q2 | $6.15M | Sell |
33,152
-5,874
| -15% | -$1.09M | 0.14% | 117 |
|
|
2025
Q1 | $8.18M | Sell |
39,026
-46,069
| -54% | -$8.96M | 0.21% | 95 |
|
|
2024
Q4 | $15.1M | Buy |
85,095
+6,162
| +8% | +$1.13M | 0.41% | 48 |
|
|
2024
Q3 | $15.6M | Buy |
78,933
+5,699
| +8% | +$1.06M | 0.44% | 47 |
|
|
2024
Q2 | $12.6M | Buy |
73,234
+1,675
| +2% | +$277K | 0.37% | 57 |
|
|
2024
Q1 | $13M | Buy |
71,559
+6,865
| +11% | +$1.18M | 0.39% | 48 |
|
|
2023
Q4 | $10M | Buy |
64,694
+5,519
| +9% | +$805K | 0.33% | 61 |
|
|
2023
Q3 | $8.82M | Buy |
59,175
+4,048
| +7% | +$594K | 0.35% | 64 |
|
|
2023
Q2 | $7.43M | Buy |
55,127
+4,919
| +10% | +$721K | 0.3% | 68 |
|
|
2023
Q1 | $8M | Buy |
50,208
+4,387
| +10% | +$671K | 0.35% | 60 |
|
|
2022
Q4 | $7.41M | Buy |
45,821
+693
| +2% | +$106K | 0.35% | 56 |
|
|
2022
Q3 | $6.06M | Buy |
45,128
+10,978
| +32% | +$1.58M | 0.32% | 66 |
|
|
2022
Q2 | $5.23M | Buy |
34,150
+21,962
| +180% | +$3.36M | 0.27% | 67 |
|
|
2022
Q1 | $1.98M | Sell |
12,188
-2,447
| -17% | -$355K | 0.1% | 136 |
|
|
2021
Q4 | $1.98M | Buy |
14,635
+1,268
| +9% | +$150K | 0.1% | 133 |
|
|
2021
Q3 | $1.44M | Buy |
13,367
+1,169
| +10% | +$134K | 0.08% | 149 |
|
|
2021
Q2 | $1.37M | Buy |
12,198
+664
| +6% | +$74.8K | 0.08% | 146 |
|
|
2021
Q1 | $1.25M | Buy |
11,534
+1,143
| +11% | +$122K | 0.1% | 134 |
|
|
2020
Q4 | $1.11M | Buy |
10,391
+243
| +2% | +$23.4K | 0.08% | 141 |
|
|
2020
Q3 | $889K | Sell |
10,148
-1,792
| -15% | -$169K | 0.08% | 150 |
|
|
2020
Q2 | $1.17M | Sell |
11,940
-923
| -7% | -$81.3K | 0.11% | 118 |
|
|
2020
Q1 | $980K | Buy |
12,863
+1,147
| +10% | +$97.7K | 0.11% | 114 |
|
|
2019
Q4 | $1.04M | Buy |
11,716
+3,057
| +35% | +$254K | 0.11% | 120 |
|
|
2019
Q3 | $656K | Buy |
8,659
+2,963
| +52% | +$203K | 0.08% | 143 |
|
|
2019
Q2 | $414K | Buy |
5,696
+2,709
| +91% | +$213K | 0.05% | 173 |
|
|
2019
Q1 | $241K | Buy |
2,987
+817
| +38% | +$66.8K | 0.04% | 207 |
|
|
2018
Q4 | $200K | Buy |
+2,170
| New | +$191K | 0.03% | 191 |
|
|
2018
Q3 | – | Sell |
-2,255
| Closed | -$209K | – | 215 |
|
|
2018
Q2 | $209K | Buy |
+2,255
| New | +$220K | 0.04% | 174 |
|
|
2018
Q1 | – | Sell |
-2,705
| Closed | -$262K | – | 172 |
|
|
2017
Q4 | $262K | Buy |
+2,705
| New | +$255K | 0.06% | 124 |
|
Other funds holding ABBV
ECSS
ATO
GAM
Empirical Wealth Management's ABBV Position: Q2 2026 in Review
Empirical Wealth Management increased its AbbVie (ABBV) stake by 2.9% in Q2 2026, buying an estimated $233K and bringing the position to 39,051 shares worth $9.83M. The position accounts for 0.14% of the portfolio, ranked #110.
Empirical Wealth Management first reported a position in ABBV in Q4 2017 and has held it in 33 quarters since. The position peaked at $15.6M in Q3 2024. 1,813 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Empirical Wealth Management held 39,051 shares of AbbVie worth $9.83M as of Q2 2026.
- Empirical Wealth Management bought 1,083 AbbVie shares in Q2 2026, an estimated $233K.
- AbbVie made up 0.14% of Empirical Wealth Management's portfolio in Q2 2026, its #110 holding.
- Empirical Wealth Management first reported a position in AbbVie in Q4 2017 and has held it in 33 quarters since.
- Empirical Wealth Management's AbbVie position peaked at $15.6M in Q3 2024.
- 1,813 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Empirical Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.